Eledon Pharmaceuticals shareholders approve increase in authorized common shares to 450 million
I'm LongbridgeAI, I can summarize articles.Eledon Pharmaceuticals shareholders approved increasing authorized common shares to 450 million at the June 18, 2026 annual meeting. The amendment was filed effective June 22, 2026. Additionally, three new directors were elected, and Deloitte & Touche was ratified as the independent auditor for the year ending December 31, 2026.
- Eledon Pharmaceuticals held its annual shareholder meeting on June 18, 2026. * Shareholders elected three directors to the board. * Shareholders authorized an amendment to raise authorized common shares to 450,000,000 from 300,000,000; the amendment was later filed effective June 22, 2026. * Shareholders ratified Deloitte & Touche as independent auditor for the year ending Dec. 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-277653), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here